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emergence in recent decades of a whole new ﬁeld of “Mitochondrial Medicine”. Molecules located on or
inside mitochondria are considered prime pharmacological targets and a wide range of efforts are underway
to exploit these targets to develop targeted therapies for various diseases including cancer. However the
concept of targeting, while seemingly simple in theory, has multiple subtly different practical approaches.
The focus of this article is to highlight these differences in the context of a discussion on the current status of
various mitochondria-targeted approaches to cancer therapy. This article is part of a Special Issue entitled:
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and “targeting”
Currently the terms target and targeting are used so commonly
that to question their meaning might seem strange. However, for the
purpose of this review we wish to ﬁrst offer our thoughts on the
concept of targeting and appropriate use and context of the terms
targeting and target. To begin with, it must be appreciated that drug
therapy at the most fundamental level is the interaction of two
molecules. An exogenous molecule administered to a patient and the
molecule in the patient that the administered molecule interacts with
to initiate a physiological response. In an ideal scenario, the
administeredmolecule interacts with only one physiological molecule
and produces a physiological response that improves a patient's
condition. In this context it is clear that the term target may be applied
to the physiological molecule and the administered molecule is a
drug. The concept of targeting on the other hand has multiple
deﬁnitions and can often be the source of confusion if not
communicated clearly.
From a drug discovery perspective, targeting is very often
described in terms of the drug molecule's ability to interact only
with the target. This concept is best described by the use of the term
selectivity and is very different from the concept of targeting from a
military perspective where the term arguably ﬁrst originated.
Consider a bullet ﬁred from a gun as an example. The object thebullet is intended to hit is the target, and the act of aiming the gun so
the bullet hits the target is what constitutes targeting. The action that
the bullet produces is destruction of the target. This action is
indiscriminate in that if the bullet hits an object other than the target,
that object will be destroyed as well. Using the gunshot analogy to
illustrate the drug discovery perspective on targeting would involve
ﬁring bullets that only destroy the target but leave the non-targets
unharmed. Most approaches to disease therapy have followed such an
argument: ﬁnding such selective molecules has been relatively easy
when there were signiﬁcant differences between the disease causing
process and normal human biochemical pathways. Not surprisingly,
infectious diseases are relatively easier to treat than inherent
disorders. The selectivity is however dose dependent and most
drugs that are considered to be selectively toxic to invading pathogens
are in fact toxic to human cells as well, but at higher doses.
The current challenges in drug therapy lie in the treatment of
diseases associated with malfunctions of normal human biochemical
pathways in certain tissues. More often than not, even dose
dependent selectivity is hard to achieve. Therefore the concept of
targeting is becoming more and more associated with selective
delivery. The term ‘targeting’ should ideally imply that themolecule is
in some way able to selectively accumulate at an intended site of
action and that the selective accumulation is associated with its
selective action. This distinction is particularly important in develop-
ing targeted therapy for a disease like cancer. Unless uniquemolecular
targets found exclusively (or at sufﬁciently higher levels) in the
diseased state and not in normal state are discovered, selective
accumulation at the disease site is crucial to the improvement of
therapy. In summary, it can be said that there appear to be two
distinct approaches to targeting in the context of drug therapy. The
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selective accumulation at the target. Most if not all examples of
targeting seem to end up being the combination of some degree of
selective action on the target and some degree of selective
accumulation at the site of the target. Improving the degree of
selective accumulation has the added advantage, even for molecules
with high target selective action, of reducing the required dose and
hence should be a major focus of all targeting approaches.
In the context of drug molecules the properties of selective
accumulation are associated with the concept of bioavailability and
biodistribution that are related to the physico-chemical properties of
themolecule. To overcome the limitations that a compound's physico-
chemical properties can impose on its potential pharmaceutical
application, the process of large-scale screening of chemical libraries
has been extended beyond identifying desired bioactivity. Screening
approaches routinely incorporate selection for physico-chemical
properties that are known to confer high bioavailability as well.
Unfortunately, this approach often leads to many potent molecules
being excluded from further development. These molecules often
have a potent pharmacological action at a desired molecular target
but aren't able to ﬁnd their way exclusively to that target. It is almost
certain that there is a growing list of such molecules that are in
essence potential drugs if only a delivery strategy can be devised to
get them to their molecular target in the human body.
Fig. 1 is a schematic representation of the levels of targeting that
might be necessary in the treatment of cancer by a targeting approach.
After systemic administration, the drug has to reach the tumor mass
that is composed of tumor cells and the supporting stroma. The
stroma, in turn, is made up of connective tissue, blood vessels, and
other non-malignant cells. Therefore, drug accumulation in a solid
tumor is only the ﬁrst step in selective action against cancer. The drug
still has to reach the tumor cell, and once inside the cell, it has to reach
its ﬁnal sub-cellular target. The sub-cellular target might be a cytosolic
molecule or more often than not, might be a molecule that is on or
inside a membrane bound organelle. In the latter case the drug must
also be able to enter the organelle and then ﬁnd its molecular target.
Currently, drug targeting is well accepted till the cellular level as
evidenced by the large number of approaches being explored to
achieve cell-speciﬁc accumulation of drugs. However, targeting at a
sub-cellular level has until recently not been as widely pursued
perhaps due to technological limitations or the argument that once a
drug gets inside a cell it will eventually ﬁnd its way to the sub-cellular
target. In the context of cancer therapy mitochondria are widely
recognized to be the location of several potential drug targets.
2. Mitochondrial targets for cancer therapy
Themitochondrion is an important organelle thatmediates several
critical processes in a eukaryotic cell. Of prime importance in the
physiology of cancer is the role of mitochondria in energy metabolismFig. 1. A schematic representation of the levels of selective accumand regulation of cell cycle. There is strong evidence to support the
rationale for the development of anticancer strategies based on
mitochondrial targets. Mitochondria are known to play a key role in
the complex apoptotic mechanism and trigger cell death via several
mechanisms that include disrupting electron transport and energy
metabolism, releasing or activating proteins that mediate apoptosis
and altering cellular redox potential. [1–3]. A critical event leading to
programmed cell death is the mitochondrial membrane permeabili-
zation, which is under the control of the permeability transition pore
complex (mPTPC), a multiprotein complex formed at the contact site
between the mitochondrial inner and outer membranes. Apoptosis
plays a central role in tissue homeostasis and it is generally recognized
that inhibition of apoptosis contributes to the transformation process
of normal cells into cancer cells [4]. The dysfunction of most apoptosis
regulating pathways has been found to be linked to various types of
cancer [5,6]. The key role of mitochondrial dysfunction and altered
apoptotic regulatory mechanisms has been appreciated for more than
a decade [7–10]. Closely allied with the dysregulation of mitochon-
drial involvement in the apoptotic process is the altered role of
mitochondria in the energy metabolism of malignant cells [11].
Cancer cells are known to favor the glycolytic process as a source of
ATP, even under aerobic conditions. Such adaptations are believed to
contribute to invasive and adaptive advantages and are often the
result of changes in mitochondrial function including mutations in
mitochondrial DNA (mtDNA) [12]. Therefore this organelle is
increasingly described as a “prime target” for pharmacological
intervention [13] and there is a growing interest in the study of the
molecular interactions of xenobiotics with cellular components
located on or inside the mitochondrion. Research by several groups
has identiﬁed various mitochondria associated molecular targets for
bioactive molecules [14–18]. These targets include mtDNA, the
mitochondrial respiratory chain, the mitochondrial permeability
transition pore complex (mPTPC), potassium channels on the
mitochondria and the various mitochondria associated anti and pro-
apoptotic factors to name a few [13,14,19]. An exhaustive discussion
of the various mechanistic pathways and all potential target
molecules in mitochondria of cancer cells has been the subject of
several excellent reviews published over the past few years [11,20–
22] and as such will not be the major focus of this article. More
relevant to the intent of this article is the discussion of current
examples of so-called mitochondrial targeting and how they ﬁt into
the concept of targeting as discussed in the previous section.With this
in mind, two major approaches can be envisioned for targeting
mitochondria in cancer cells. The ﬁrst involves the use of molecules
that act exclusively on molecular targets in mitochondria of cancer
cells without having any marked predisposition for preferentially
accumulating in mitochondria. The second approach involves deliv-
ering molecules capable of affecting mitochondrial function exclu-
sively to the mitochondria of cancer cells. Of course as discussed
earlier the two approaches need not be exclusive with the bestulation required in a mitochondria-speciﬁc targeting strategy.
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mitochondria and a delivery strategy aimed at achieving its
mitochondria-speciﬁc accumulation in cancer cells.
3. The selective action approach to targeting mitochondria of
cancer cells
There are numerous molecules currently in use or being tested in
clinical trials that act on mitochondria [11]. Several clinically
approved anticancer drugs such as paclitaxel [23–25], VP-16 (etopo-
side) [26] and vinorelbine [25] as well as an increasing number of
experimental anticancer drugs such as, ceramide [27], MKT077 [28]
and CD437 [29–31], lonidamine [32,33], betulinic acid [34–36] have
been found to act directly on mitochondria to trigger apoptosis [37].
CD437 is able to induce apoptosis in a variety of human carcinoma
cells in vitro and in vivo [38]. In intact cells, CD437-dependent caspase
activation is preceded by the release of cytochrome C from
mitochondria [31]. Moreover, when added to isolated mitochondria,
CD437 causes membrane permeabilization. This effect is prevented by
inhibitors of the mitochondrial permeability transition pore complex
(mPTPC), such as cyclosporine A. Therefore, CD437 represents a low
molecular weight compound, which exerts its cytotoxic effect via the
mPTPC, i.e., by acting directly at the surface or inside of mitochondria.
Similarly, arsenic trioxide, which is used in the treatment of acute
promyelocytic leukemia, has multiple actions on mitochondria. It is
known to cause the induction of mPTPC formation via its action on the
voltage-dependent anion channel VDAC [39]. Arsenic trioxide is also
known to act on the respiratory chain and inhibit respiratory chain
activity [40].
Apoptotic factors that play a major role in the modulation of
apoptosis include Bcl-2 and Bcl-Xl. Compounds that act by binding to
these proteins have been identiﬁed and studied for their efﬁcacy, a
few examples include a chromene derivative [41], and gossypol which
was recently shown to act on proteins of the Bcl-2 family [42]. In fact
there are so many varied and structurally different compounds that it
has been suggested that they be collectively called mitocans to reﬂect
their mitochondrially mediated anticancer effects [43–45].
Unfortunately, despite the seemingly large list of compounds that
can interfere with mitochondrial function [11], it is still unclear as to
what extent these molecules can selectively accumulate at the tumor.
Therefore most, if not all, of the molecules described so far can
potentially beneﬁt from selective delivery to the tumor. For example the
rhodacyanin compound MKT-077 was investigated in clinical trials on
the basis of its ability to selectively accumulate in mitochondria and
inhibit ATP synthesis [28,46]. Despite exhibiting a prolonged retention
in mitochondria of cancer cells compared to non-cancer cells, the drug
was found to cause signiﬁcant nephrotoxicitywith amechanism related
tomitochondrial dysfunction [28]. The drugwas therefore rejected from
phase II trials. It is very likely that the toxicity resulted from the
distribution of signiﬁcant portions of the administered dose to non-
tumor sites. If so, a tumor-speciﬁc delivery strategy could improve the
therapeutic prospects for this drug.
In the case of molecules that do not exhibit the marked
mitochondria-speciﬁc accumulation of MKT-077, tumor-speciﬁc
delivery must further be combined with a strategy to achieve
mitochondria-speciﬁc accumulation once inside the cell. Although
not directly related to an anticancer strategy Cyclosporin A (CsA)
provides a good example of a drug that requires a mitochondria-
speciﬁc delivery strategy. CsA has been shown to bind with
nanomolar afﬁnity to mitochondrial cyclophilin D, which potentially
makes it an interesting antiischemic drug candidate [47]. However,
CsA also targets various other cyclophilins inside the cell, which are
each likely to bind some portion of the administered drug. Therefore,
the mitochondrial concentration of CsA is difﬁcult to predict and an
effective CsA treatment may require high, even toxic concentrations
to elicit an effect at the mitochondrial target [48]. Consequently, amitochondria-speciﬁc delivery approach would potentially improve
the therapeutic beneﬁt of CsA [49]. Similar scenarios exist among the
anticancer drugs. Paclitaxel, for example is generally known as an
anti-microtubule agent but has also recently been demonstrated to
trigger apoptosis by directly acting on mitochondria [23–25].
Clinically relevant concentrations of paclitaxel can trigger apoptosis
by inducing cytochrome C release in a mPTP-dependent manner. This
mechanism of action is also associated with other pro-apoptotic
agents known to directly act onmitochondria [35]. A twenty four hour
delay between the treatment with paclitaxel or with other PTP
inducers and the release of cytochrome C in cell-free systems
compared to intact cells has been attributed to the existence of
several drug targets inside the cell and only a fraction of the total
intracellular drug being available for action on mitochondria [23].
Anti-tubulin agents such as vinorelbine or nocodazole have been
shown to trigger the release of cytochrome C via the direct interaction
with mitochondria [50], which subsequently resulted in apoptotic cell
death. Etoposide which is a mitochondrial topoisomerase inhibitor, is
known to act at a higher concentration by inducing the release of
apoptotic factors while at a lower concentration it acts by causing
nuclear DNA damage [51].
Therefore, in the more than likely scenario that potential drug
molecules do not exhibit adequate tumor and mitochondria-speciﬁc
accumulation, a concerted effort to develop tumor-targeted mito-
chondria-speciﬁc approaches might be signiﬁcant aid towards
exploiting mitochondrial targets for cancer therapy.
4. The selective accumulation approach to targeting mitochondria
of cancer cells
As illustrated in Fig. 1 the selective accumulation approach to
targeting tumor mitochondria requires two levels of speciﬁc accu-
mulation; drug accumulation in the tumor and then drug accumula-
tion in the mitochondria of cancer cells. Generally speaking, drug
disposition may be modulated by subtle modiﬁcation of the chemical
structure to change its physico-chemical properties that are known to
determine its accumulation in various compartments. Of course such
modiﬁcation must be done without adversely affecting action on the
molecular target. The second approach involves conjugating ligands
that are larger than simple organic functional groups to change the
biodistribution of the active molecule. Again this approach works as
long as the conjugation does not adversely affect the desired
pharmacological activity of the molecule. Such approaches have
been used very effectively to alter drug distribution in the body and
achieve higher accumulation in target tissues using ligands that are
known to have an afﬁnity for the target tissue. There are ligands that
have been shown to mediate tumor-speciﬁc accumulation of drugs,
and there are ligands that are knownmitochondriotropics. However it
is still unclear whether there exists a ligand that possesses both
properties to a degree that will allow high levels of the desired
accumulation. It may therefore be safe to say that, for now, a dual
strategy is the most feasible approach. Such a dual strategy would
require the use of one targeted delivery approach to achieve high
tumor accumulation followed by a second approach to ensure that the
drug then accumulates in the mitochondria where it will exert its
action. While there is much investigation into tissue-speciﬁc delivery
aimed at increasing tumor levels of anticancer drugs, research aimed
at sub-cellular delivery is only just gaining more attention [52,53].
Nonetheless there are some interesting approaches to mitochondrial
delivery that suggest the promise of improved therapy for cancer.
4.1. Molecular modiﬁcation approaches for selective accumulation in
mitochondria
The interior of a cell is very different from a dilute aqueous
solution, in which small drug molecules can freely diffuse and
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cytoskeletal network, discrete organelles and a multitude of macro-
molecules [54,55] and other dissolved biomolecules produce a highly-
constrained environment much different from that in which classical
Fickian diffusion is likely to be the dominant mode of non-speciﬁc
transport [56,57]. The ﬂuid-phase viscosity of the cytoplasm, and the
binding to intracellular components are also believed to inﬂuence the
diffusion of solutes inside a cell [58,59] and efforts towards
understanding such parameters are already underway [60]. Properties
of the medium aside, it is generally accepted that the physico-
chemical properties of the drug also play a major role in determining
the sub-cellular fate of the drug molecule. Therefore, the ability to
predict the inﬂuence of various properties of the drugmolecule on the
likely site of accumulation within the cell is a powerful tool to either
select molecules with the desired mitochondrial accumulation or
identify molecules that would beneﬁt from mitochondria-speciﬁc
delivery strategies. To this end, a Quantitative Structure Activity
Relationship (QSAR) model for predicting cellular uptake and
intracellular distribution of low molecular weight compounds has
been proposed [61]. This QSAR approach was recently applied to
identify potential common chemical features of molecules that are
known to selectively accumulate at or inside mammalian mitochon-
dria within living cells [62]. The QSAR approach has additionally
proven useful for the modeling of cationic transfection lipids [63] and
could therefore be applicable to predicting the sub-cellular disposi-
tion of a potential therapeutic molecule and even to assist in the
selection of structural modiﬁcation of therapeutic molecules to impart
the desired mitochondrial afﬁnity. A survey of the literature reveals
that the most commonly used mitochondrotropic molecule is the
triphenylphosphonium (TPP) cation. Conjugation of a TPP cation has
been used to deliver various bioactive cargos to mitochondria
including antioxidants like coenzyme Q, ubiquinone and various
nitroxides [64]. The TPP cation was also used to deliver peptide
nucleic acids [65] and Cyclosporin A to mitochondria indicating the
broad applicability of such an approach to mitochondria-speciﬁc
delivery. However, more recently and of more direct relevance to the
discussion on cancer therapy is the use of the TPP cation to modify
porphyrins for potential mitochondria-targeted photodynamic ther-
apy. Meso-tetraphenylporphyrin derivatives bearing either the
triphenylphosphonium ion or the triethylammonium ion were
shown to be mitochondria-targeted and to exhibit light dependent
toxicity in MCF-7 human breast cancer cell line, suggesting their
application potential in photodynamic therapy. Additionally the
triphenyl phosphonium cation and various other mitochondriotropic
residues were used to synthesize several examples of a class of
molecules described as geldanamycin mitochondrial matrix inhibitors
(Gamitrinibs). Gamitrinibs are designed to selectively target and
inhibit Hsp90 activity in mitochondria of human carcinoma cells by
acting as ATPase antagonists. Most interesting is the claim that
gamitrinibs are non-toxic to non-cancer cells and have no effect on
Hsp90 function in non-mitochondrial sub-cellular compartments. The
drug TEMPOL also provides a very interesting example of the
application of a conjugation approach to improve mitochondrial
targeting. TEMPOL is a piperidine nitroxide that acts as a prodrug and
is reduced to a hydroxylamine in mitochondria by ubiquinol. The
metabolite induces apoptosis in cancer cells by action on complex I
[66]. Conjugation of a TPP residue to TEMPOL improved its
mitochondria-speciﬁc accumulation and its reaction with ubiquinol
in mitochondrial membranes [67].
In addition to the so-called delocalized cations [68] like TPP,
rhodamine and various other mitochondria-speciﬁc stains, there
exists another distinct class of mitochondria-speciﬁc delivery ligands.
The various mitochondrial matrix proteins that are synthesized in the
cytosol and imported into the matrix by the mitochondrial import
machinery rely on short leader sequences to mediate this speciﬁc
import process. Just like the TPP cation, the leader sequences ofvarious matrix proteins have also been used to mediate the
mitochondria-speciﬁc accumulation of a variety of bioactive mole-
cules [69]. Based on the rationale that short peptides can exhibit
mitochondria-speciﬁc localization, the pro-apoptotic and potential
anticancer peptide (KLAKLAK)2 was engineered to improve mito-
chondrial localization [70]. Further, a recent report that conjugation to
bombesin enhanced the cytotoxicity of threemitochondria-disrupting
peptides through improvement of their binding afﬁnity makes a case
for the conjugation approach in improving the tumor association of
agents that already possess mitochondria-speciﬁc action [71]. This
raises an interesting question of whether or not it is possible to have a
ligand that can mediate both tumor-speciﬁc delivery and mitochon-
dria-speciﬁc delivery inside the tumor cells. This may still be asking
too much from a single molecule. There exist three alternatives. The
ﬁrst is the use of a dual conjugation strategy with two ligands
conjugated to the same active molecule. Second is the use of a tumor-
speciﬁc nanocarrier to deliver an active molecule that has been
conjugated to a mitochondria-speciﬁc ligand. The ﬁnal alternative is
the use of a tumor-speciﬁc andmitochondria-speciﬁc nanocarrier. The
development of nanocarrier-based approaches thus becomes an
integral part of mitochondria-targeted approaches to cancer therapy.
4.2. Nanocarrier based approaches for selective accumulation in
mitochondria
Pharmaceutical nanocarriers like liposomes and micelles, solid
nanoparticles offer whatmight be viewed as a non-chemical approach
to modify the disposition of drug molecules. All chemistry can be
performed on the components of the nanocarrier system that can then
be loaded with the drug to afford targeted delivery [72–75]. Most
pharmaceutical nanocarriers can be modiﬁed for targeting to speciﬁc
tissues and even speciﬁc cell types. Long-circulating liposomes and
nanoparticles are able to passively target areas of leaky vasculature by
virtue of the enhanced permeability and retention (EPR) effect and
can additionally be modiﬁed with antibodies or other targeting
ligands to afford cell-speciﬁc recognition [76–80]. Nanocarriers that
cannot only effect the tumor-speciﬁc accumulation of a drug but also
mediate mitochondria-speciﬁc accumulation within a tumor cell
might be the ultimate tool in mitochondria-targeted anticancer
approaches if they can be developed for clinical therapy. The ﬁrst
steps in this direction have already been taken in recent years. Current
nanocarrier technology is reaching the point where the need for sub-
cellular delivery may indeed be met using nanocarriers speciﬁcally
designed for such purposes.
In an approach towards the delivery of the mPTPC inducing drug
mastoparan into cells [81] liposomes were modiﬁed with both
transferring and a fusogenic peptide Chol-GALA. The transferrin
modiﬁcation enhances liposomal uptake into cells via endocytosis
after which the peptide facilitates release from the endosomes into
the cytosol. Thus, by just increasing the intracellular content of the
drug, the delivery approach achieved a higher concentration of the
drug that was potentially available to interact with the sub-cellular
target. Micelles have also been proposed for the delivery of
hydrophobic drugs to various sub-cellular organelles including
mitochondria [82]. The ﬂuorescently labeled micelles used in the
study were found to be distributed through several cytoplasmic
organelles including a majority of them being associated with the
mitochondria. The uptake of these micelles was not restricted to a
single cell type. Also, the extent of cell internalized cargo incorporated
in micelles was greater than the free cargo by itself. There are now
several examples of nanocarriers designed speciﬁcally to accumulate
in mitochondria. Arguably the earliest of these are what are known as
DQAsomes. Prepared from the mitochondriotropic molecule dequa-
linium chloride, these vesicular nanocarriers were developed for
mitochondria-speciﬁc DNA delivery but were also shown to be
capable of changing the sub-cellular distribution of paclitaxel to
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mitochondria-speciﬁc delivery led to improved apoptotic activity at
paclitaxel concentrations, at which the free drug does not have a
signiﬁcant cytotoxic effect [83]. Paclitaxel loaded DQAsomes have also
been tested for their ability to inhibit the growth of human colon
cancer tumors in nude mice [84] and the data strongly suggest that
encapsulation of paclitaxel in DQAsomes leads to improved efﬁcacy.
The antitumor efﬁciency of DQAsomal encapsulated paclitaxel was
also further enhanced by modifying the DQAsomal surface with folic
acid (FA) [85]. The folate receptor is a folate high-afﬁnity membrane
binding protein, which is overexpressed in a large variety of human
tumors [86–88]. FA conjugates are internalized in a tumor cell-speciﬁc
manner by receptor-mediated endocytosis resulting in an increased
toxicity of the corresponding drug [89–91]. Cell cytotoxicity studies
using folate receptor expressing HeLa cells suggested that folic acid
conjugated DQAsomes possess better antitumor activity as compared
to plain paclitaxel loaded DQAsomes, folic acid conjugated paclitaxel
loaded liposomes and the free drug. Based on the data it was
concluded that folic acid conjugated DQAsomes delivered the drug
not only to the cytosol but also to mitochondria whereas folic acid
conjugated liposomes delivered the drug into the cytosol only [85].
Another approach to the design of mitochondria-speciﬁc nano-
carriers is to modify existing nanocarriers with mitochondriotropic
ligands. In this regard TPP again served as the mitochondriotropic
ligand in liposomal and polymer based nanocarriers. Liposomes have
been well characterized as delivery systems and are a popular choice
due to their biocompatibility, ease of surface modiﬁcation, capacity to
encapsulate hydrophilic or hydrophobic drugs [92]. The ﬁrst indica-
tion that liposomes could be rendered mitochondriotropic by surface
modiﬁcation with a mitochondriotropic residue came from a report
that so-called proteoliposomes prepared by incorporating a crude
mitochondrial membrane fraction into liposomes colocalized with
endogenous mitochondria in pre-implantation embryos [93]. Further
investigation of the concept of using ligands to alter the sub-cellular
distribution of liposomes was based on the synthesis of stearyltri-
phenylphosphonium (STPP) [94]. The stearyl residue of STPP serves as
a lipid anchor to modify the surface of liposomes with the TPP residue
and resulted in a liposomal preparation with a marked predisposition
for mitochondria [94]. STPP-liposomes were shown to effectively
direct the accumulation of rhodamine labeled phosphatidylethanol-
amine (Rh-PE) to mitochondria in live cells [95]. Based on ﬂow
cytometry STPP-liposomes exhibited the same level of cell association
as liposomes with the same cationic charge. However, the subsequent
sub-cellular localization analyzed by confocal microscopy was
markedly different indicating that the mitochondriotropic ligand
and not the surface charge is what determines mitochondria-speciﬁc
association of the nanocarrier [95]. It was also found that the TPP
ligand did not change the in vivo distribution and tumor accumulation
of long-circulating PEGylated liposomes. STPP-liposomes did however
improve the both the in vitro and the in vivo efﬁcacy of ceramide.
Taken together these data suggest that the tendency of long-
circulating liposomes to passively accumulate (via the EPR effect) in
solid tumors can be combined with organelle-speciﬁc tropism
conferred by modiﬁcation with an appropriate ligand to potentiate
the effect of an encapsulated antitumor agent.
An alternative approach to developing mitochondria-speciﬁc lipo-
somes has focused on the concept that liposomes with a tendency to
selectively fuse with mitochondrial membranes are more likely to
associatewithmitochondria upon cell entry. Referred to asMITO-Porter,
these liposomes are surface modiﬁed with octaarginine residues to
facilitate their entry into cells as intact vesicles (via macropinocytosis)
[96]. The lipid composition was selected on the basis of high levels of
fusion with themitochondrial membrane and the release of its cargo to
the intra-mitochondrial compartment in living cells [96]. Based on
confocal microscopy data, MITO-porter liposomes have been used to
deliver greenﬂuorescentprotein [96] aswell aspropidium iodide [97] tomitochondria suggesting that they can be used to deliver macromole-
cules as well as small molecules to mitochondria.
The development of mitochondria-speciﬁc nanocarriers has not
been limited to lipid based carriers but also includes the use of
mitochondriotropic residues to create polymeric systems capable of
mitochondria-speciﬁc intracellular delivery of bioactive molecules [98–
100]. TPP modiﬁcation has been employed to create a mitochondrio-
tropic N-(2-hydroxylpropyl)methacrylamide (HPMA) copolymer-
based nanoparticle [99,100]. Interestingly the ﬁrst study indicated that
while the polymers characterized did exhibit association with isolated
mitochondria, experiments with ovarian carcinoma cells revealed
predominantly lysosomal association of the polymer [99]. However, in
themore recent study [100]microinjection and incubation experiments
performed using ﬂuorescently labeled constructs suggested mitochon-
drial targeting ability based on microscopic analysis. Subsequently,
HPMA copolymer-drug conjugates were synthesized using a photosen-
sitizer mesochlorin e 6 (Mce 6). Mitochondrial targeting of HPMA
copolymer-bound Mce 6 enhanced cytotoxicity as compared to non-
targetedHPMAcopolymer-Mce6 conjugates [100]. The authors indicate
that “minor modiﬁcations may be required to adapt the current design
and allow for tumor site-speciﬁc mitochondrial targeting of other
therapeutic agents” [100]. Therefore these systems could theoretically
be applied to the mitochondria-speciﬁc delivery of a range of pro-
apoptotic substances for cancer therapy.
Inorganic nanoparticles have also been shown to be capable of
mitochondria-speciﬁc delivery. In a very recent study, hypocrellin A, a
photodynamic drug, was encapsulated in a water-soluble amorphous
silica nanocage (HANC) [101]. These drug-loaded nanocages are
reportedly able to speciﬁcally accumulate in the mitochondria of
cancer cells and improve the photosensitizing effect of hypocrelin A.
[101]. It is however unclear what mediates the mitochondria-speciﬁc
accumulation of the nanocage system. Nevertheless, taken together,
the various studies described so far strongly support the hypothesis
that nanocarriers can indeed control the sub-cellular accumulation of
bioactive molecules and as such represent a useful tool in the
development of mitochondria-targeted anticancer strategies.
5. Conclusions and perspectives
The recognition of the role thatmitochondria play in human health
and disease is evidenced by the emergence in recent decades of a
whole new ﬁeld of “Mitochondrial Medicine” [102,103]. As discussed
so far, targeting mitochondrial molecules in the development of
cancer therapy relies on the two basic interpretations of targeting via
selective action on the target and selective accumulation at the target
site where the term target must represent a molecule and not a
particular tissue or cell location. Table 1 provides a summary of
current examples on the basis of these broad classes. Irrespective of
the level of selective action that a molecule possesses, it can be argued
that a selective delivery strategy is desirable. In the case of molecules
with ideal selective action, selective delivery allows economical
dosing while in the case of molecules with signiﬁcant off target
accumulation and effects, selective delivery also offers improved
safety. It must be appreciated that the probability of ﬁnding a single
molecule with ideal selective effect in diseases like cancer is very low
given the very subtle differences in cancer cell-speciﬁc targets from
normal cells. Evenmore improbable is the existence of molecules with
both ideal selective action and selective accumulation. Therefore drug
discovery studies must include approaches aimed at conferring
selective accumulation on molecules with promising selective action.
Direct conjugation to ligands that mediate the desired tumor and sub-
cellular accumulation has been used effectively and therefore offer
signiﬁcant promise. Pharmaceutical nanocarriers offer much promise
for tumor-speciﬁc delivery and have also recently been explored for
sub-cellular delivery. We expect that an ideal approach to mitochon-
drial targeting in cancer therapy might therefore be represented by
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694 G.G.M. D'Souza et al. / Biochimica et Biophysica Acta 1807 (2011) 689–696the identiﬁcation of a molecule with a high level of selective action on
the mitochondrial target. The molecule may then be conjugated with
a mitochondria-speciﬁc ligand and then loaded into a tumor cell
targeting nanocarrier, thus conferring in one composite system, all the
required levels of selective accumulation and selective action to
constitute a truly targeted approach.References
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